- Home
- STSS vs TCBP Comparison
STSS vs TCBP Comparison
Compare STSS & TCBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STSS
- TCBP
- Stock Information
- Founded
- STSS 2017
- TCBP 2013
- Country
- STSS United States
- TCBP United Kingdom
- Employees
- STSS N/A
- TCBP 41
- Industry
- STSS Medical/Dental Instruments
- TCBP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STSS Health Care
- TCBP Health Care
- Exchange
- STSS Nasdaq
- TCBP Nasdaq
- Market Cap
- STSS 3.0M
- TCBP 3.3M
- IPO Year
- STSS 2022
- TCBP 2022
- Fundamental
- Price
- STSS $0.32
- TCBP $0.36
- Analyst Decision
- STSS
- TCBP Strong Buy
- Analyst Count
- STSS 0
- TCBP 1
- Target Price
- STSS N/A
- TCBP $2.40
- AVG Volume (30 Days)
- STSS 2.4M
- TCBP 889.4K
- Earning Date
- STSS 03-31-2025
- TCBP 11-25-2024
- Dividend Yield
- STSS N/A
- TCBP N/A
- EPS Growth
- STSS N/A
- TCBP N/A
- EPS
- STSS N/A
- TCBP N/A
- Revenue
- STSS N/A
- TCBP N/A
- Revenue This Year
- STSS N/A
- TCBP N/A
- Revenue Next Year
- STSS N/A
- TCBP N/A
- P/E Ratio
- STSS N/A
- TCBP N/A
- Revenue Growth
- STSS N/A
- TCBP N/A
- 52 Week Low
- STSS $0.30
- TCBP $0.25
- 52 Week High
- STSS $18.15
- TCBP $32.70
- Technical
- Relative Strength Index (RSI)
- STSS 12.70
- TCBP 34.95
- Support Level
- STSS $0.34
- TCBP $0.27
- Resistance Level
- STSS $0.42
- TCBP $0.41
- Average True Range (ATR)
- STSS 0.13
- TCBP 0.05
- MACD
- STSS -0.15
- TCBP 0.02
- Stochastic Oscillator
- STSS 1.12
- TCBP 31.19
About STSS Sharps Technology Inc.
Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa, Securgard, and Sologard are ultra-low waste smart safety syringes are designed to eliminate potentially infectious and accidental needlestick injuries.
About TCBP TC BioPharm (Holdings) plc
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.